developed-europe-header

Developed Europe

Our Developed Europe business is made up of operations in Europe’s major developed countries. The Anaesthetics and Thrombosis portfolios are the leading therapeutic focused brands in Developed Europe.
The API site at Oss, supported by its satellite operation at Sioux City, supplies APIs worldwide. The Notre Dame de Bondeville and Bad Oldesloe sites are strategically important manufacturers for the Group.

Key Countries

France
Germany
Italy
The Netherlands
United Kingdom

Contribution to Group revenue

developed-europe-contrib-1

Revenue contribution - by therapeutic category

developed-europe-1
  • The injectable anticoagulants category in Developed Europe recorded flat volume growth and made up 75% of the total anticoagulants (injectables and orals).
  • The Anaesthetics category in Developed Europe grew 1,1% by value across all products to EUR1,3 billion as at 30 May 2018. General anaesthetics made up 50,3% of total value and grew 3,7% for the year.

Source: May 2018 IMS

STATISTICS

Number of products launched:

Nil

(2017: nil)

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:

0 – 2 years

USDnil

3 – 5 years

USDnil

Number of product recalls:

7

(2017: 2)

Average staff turnover:

8,4%

(2017: 9,7%)

Number of work-related fatalities:

Nil

(2017: nil)

Number of permanent employees:

developed-europe-employees

Revenue – R’billion20182017 (CER) % change
Total12 32911 8714
Commercial Pharmaceuticals7 4346 9417
Regional Brands376476(21)
Anaesthetics2 1701 73225
Thrombosis3 4713 2048
High Potency & Cytotoxics1 4171 529(7)
Manufacturing4 8954 930(1)
– API4 2594 2630
– FDF636667(5)

Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.